Product Description
When PF-06687234 is added to Infliximab, it may further decrease the inflammation of Ulcerative Colits and thus provide relief of your symptoms.
Mechanisms of Action: IL10 Agonist
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DekaJoint | P1 |
Not yet recruiting |
Arthritis, Rheumatoid |
2025-12-31 |
37% |
2022-11-19 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/01/2022 |
News Article |
Philogen Reports Full Year 2021 Results and Provides Corporate Update |
|
11/12/2021 |
News Article |
Philogen Provides Corporate Update |
|
11/12/2021 |
News Article |
Philogen Provides Corporate Update |
|
09/29/2021 |
News Article |
Philogen Provides Corporate Update |